Breast Cancer Registry Platform

N/AActive Not RecruitingNCT03417115

iOMEDICO AG5,000 enrolled

Overview

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with breast cancer in Germany.

OPAL is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life in patients with breast cancer will be evaluated for up to five years.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Breast Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: EBC cohort: * Female and male patients with early breast cancer (stage I-III defined as breast cancer that has not spread beyond the breast or the axillary lymph nodes) * Patients at the start of their initial systemic treatment for EBC, i.e. at start of neoadjuvant treatment for patients receiving neoadjuvant thera-py or at start of adjuvant treatment if no neoadjuvant therapy is given. Treatment can be cytotoxic, endocrine, or targeted substances, what-ever was given first ABC cohort: * Female and male patients with advanced breast cancer (stage IV defined as synchronous or metachronous diagnosis of distant metastases at inclusion) * Patients at the start of their initial first-line systemic treatment for ABC, which can be cytotoxic, endocrine or targeting a specific signaling pathway, whatever is given first All cohorts: * Written informed consent * Patients participating in the PRO module: signing of informed consent form and completion of baseline questionnaire before start of initial systemic treatment for EBC or systemic first-line treatment for ABC * Patients not participating in the PRO module: within six weeks after start of initial systemic treatment for EBC or systemic first-line treatment for ABC * Age ≥ 18 years Exclusion Criteria: * Patients with prior systemic therapy (cytotoxic, endocrine, or targeted) for EBC or ABC * Patients who do not receive any systemic therapy for EBC or ABC

Locations (1)

Multiple sites all over germany

Many Locations, Germany

Outcomes

Primary Outcomes

Treatment reality

Description of treatment reality (Course of systemic treatments and sequential treatments) applied in German routine practice measured as the frequency of the various systemic treatments applied per line of therapy.

Time frame: 5 years

Secondary Outcomes

Best Response

Documentation of response rates per line of treatment.

Time frame: 5 years

Progression-free survival

Documentation of progression-free survival per line of treatment.

Time frame: 5 years

Overall survival

Documentation of date of death.

Time frame: 5 years

Health-related quality of life (Patient-reported outcome)

EORTC QLQ-C30 core questionnaire and additional items.

Time frame: 3.5 years

Disease-free survival

Documentation of disease-free survival.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.